Pharmacokinetic Study of Levetiracetam in Children

Pellock, John M.; Glauser, Tracy A.; Bebin, E. Martina; Fountain, Nathan B.; Ritter, Frank J.; Coupez, René; Shields, W. Donald

doi:10.1046/j.1528-1157.2001.41300.x

Cited by 142 publications

(135 citation statements)

References 12 publications

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…The pharmacokinetic profile in pediatric patients shows that levetiracetam is cleared more quickly and also shows significant interindividual variability (16). Therefore, pediatric patients require higher dosage, and it is crucial to measure the amount of drug in patient's blood for effective treatment (16,17). Apart from evaluating toxicity, therapeutic drug monitoring for levetiracetam is used in adjusting dosage for renal insufficiency.…”

Section: Discussionmentioning

confidence: 99%

Validation of an Automated Assay for Levetiracetam (Keppra) on Vitros 5600

Ali

Tam

Roper

et al. 2017

The Journal of Applied Laboratory Medicine

View full text Add to dashboard Cite

Objective Levetiracetam (also known as Keppra™) is an antiepileptic drug that has been demonstrated as an effective adjunctive therapy in the treatment of partial onset of seizures, primary generalized tonic-clonic seizures, and myoclonic seizures. The aim of our study was to validate an automated quantitative immunoassay for levetiracetam at Texas Children's Hospital. Method We validated the analytical performance of ARK™ Levetiracetam Assay on an Ortho Clinical Diagnostic Vitros 5600 Analyzer at Texas Children's Hospital. Analytical performance parameters included precision, linearity, sensitivity, accuracy, and effect of common interferents (free hemoglobin, bilirubin, triglycerides). We also tested common drug interferents on the ARK Levetiracetam Assay. Results The assay showed good precision with <4% coefficient of variation (%CV) for intraassay and <7% for interassay precision, respectively. The assay was linear across the measurement range (0.0–100.00 μg/mL). No significant effect was seen with common interferents or commonly co-used drugs. Conclusions The ARK Levetiracetam Assay on Ortho Clinical Diagnostic Vitros 5600 can be used for routine determination of levetiracetam for conducting therapeutic drug monitoring and optimizing individual dosage regimen.

show abstract

Section: Discussionmentioning

confidence: 99%

Validation of an Automated Assay for Levetiracetam (Keppra) on Vitros 5600

Ali

Tam

Roper

et al. 2017

The Journal of Applied Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…Consequently, normal levels of SV2 and synaptotagmin at the synapse are maintained, which may lead to reduce seizures (1,3). Also, it is suggested that LEV partially inhibits N-type high-voltage-activated Ca 2+ currents and reduces the release of Ca 2+ from intraneuronal stores (4)(5)(6)(7)(8)(9). LEV has a favorable pharmacokinetic profile.…”

Section: Contextmentioning

confidence: 99%

Add-on Levetiracetam in Children With Refractory Epilepsy: A Systematic Review

Abbaskhanian

Shahmohammadi

2016

J Pediatr Rev

View full text Add to dashboard Cite

Context: Recently, new anti-epileptic drugs are marketed to be used as an add-on to the traditional drugs in children with refractory epilepsy. Levetiracetam is a second-generation of new anti-epileptic drugs with unknown precise mechanism of action in brain and synaptic vesicle in children with drug resistant epilepsy. Herein, the efficacy and safety of add-on levetiracetam in children with refractory epilepsy is reviewed.Evidence Acquisition: A literature review was performed on efficacy and safety of add-on Levetiracetam in children with refractory epilepsy using international databases with the following terms: levetiracetam, refractory epilepsy, drug resistant epilepsy, seizures/epilepsy, children/pediatric. All articles related to add-on levetiracetam in children with refractory epilepsy written in English and published from 2000 to 2015 were included. The title and abstracts of 542 articles were assessed, of which, 488 were excluded. The full texts of the other 54 articles were assessed for relevance. Results:Of the nine eligible articles, 1036 patients aged ≤ 18 years were identified. Male patients (52%) were more prominent than female ones. Five articles reported that levetiracetam therapy appeared more effective against localization-related than generalized epilepsy. The dosage of levetiracetam ranged from 6 to 70 mg/kg/day, with a mean of 43.2 mg/kg/day based on the mean doses reported by four of nine reviewed articles. The mean duration of follow-up was 39 weeks (ranging from 8 -144 weeks). Administration of levetiracetam was effective in 42.24% of the patients (responders with >50% decrease in seizure frequency), of whom 11.8% had become seizure free. The mean number of anti-epileptic drugs tried before introducing levetiracetam treatment was 4.4 (ranging 1 -20). The most frequent side effects were psychological and behavioral changes (11.1%), followed by agitation (9.2%) and sleep disturbances (6.7%). Conclusions:The current review demonstrated that levetiracetam, as an add-on therapy, is an effective and well-tolerated antiepileptic drug, associated with reversible and no serious side effects, to control seizure frequency of childhood refractory epilepsy.

show abstract

“…Наличие раствора для приема внутрь -очень большой плюс, принципиально отличающий кеппру от других ПЭП и дженериков левети-рацетама [47,54,56,57]. Имеющиеся в настоящее время данные о применении леветирацетама позволяют реко-мендовать его также для стартовой монотерапии юноше-ской миоклонической эпилепсии у женщин [53,58].…”

Section: эпилепсия у детейunclassified